Abstracts tagged "Disease Activity"

Abstract Number: 1763 • 2018 ACR/ARHP Annual Meeting
Characterizing the Gut and Plasma Metabolomes in Patients with ANCA-Associated Vasculitis
Catherine E. Najem¹, Jung-Jin Lee², Ceylan Tanes², Cassidy Strange², Elliot Friedman², Antoine G. Sreih¹, Rennie L. Rhee¹, Abdallah Geara³, Hongzhe Li⁴, Kyle Bittinger², James D. Lewis⁵, Gary Wu⁵ and Peter A. Merkel⁴, ¹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Nephrology and Hypertension, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, ⁵Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA
Background/Purpose:To explore the mechanisms by which an altered gut microbiota might predispose to ANCA-associated vasculitis (AAV), a comprehensive metabolic profiling of fecal and plasma bile…
Abstract Number: 2431 • 2018 ACR/ARHP Annual Meeting
Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis
Chelsey J F Smith¹, Arthur Kavanaugh² and Christina D Chambers³, ¹Rheumatology, University of California San Diego, La Jolla, CA, ²University of California, San Diego, School of Medicine, La Jolla, CA, ³University of California San Diego Department of Pediatrics, La Jolla, CA
Background/Purpose: The goal of this prospective cohort study is to add to the limited data on birth outcomes in psoriatic arthritis (PsA) and ankylosing spondylitis…
Abstract Number: 2625 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitor Reduces ASDAS Faster and More Stable in Ankylosing Spondylitis Patients: Results from a Real World Prospective Cohort Managed By Smart Phone System
Xiaojian Ji, Jian Zhu, Jianglin Zhang and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose: The Smart-phone Spondyloarthritis Management System (SpAMS) is a mobile health tool, specifically designed to conduct prospective clinical studies on SpA/AS in China, using real-world…
Abstract Number: 2949 • 2018 ACR/ARHP Annual Meeting
African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in B Cells and TLR7/8 Pathways
Samantha Slight-Webb¹, Miles C. Smith¹, Holden T. Maecker², Paul J. Utz³, Joel M. Guthridge¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Stanford University, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder with a heterogeneous clinical presentation and periods of waxing and waning disease. Heterogeneity in SLE is…
Abstract Number: 321 • 2018 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis All Disease Activities Are Not Created Equal
Keith Knapp¹ and Gary Craig², ¹Discus Analytics LLC, Spokane, WA, ²Discus Analytics LLC., Spokane, WA
Background/Purpose: Multiple composite RA disease activity (DA) metrics are approved for use; each reflect different aspects of disease. Many use similar measurements but their values…
Abstract Number: 589 • 2018 ACR/ARHP Annual Meeting
DAS28-CRP Versus DAS28-ESR and Thresholds for Disease Activity Category: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Cristina Vitalini, Beatrice Barbetta, Giampaolo Giacovelli, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: In most patients with rheumatoid arthritis (RA) the 28-Joint Disease Activity Score (DAS28) values calculated using C-reactive protein (CRP) are lower than those calculated…
Abstract Number: 1192 • 2018 ACR/ARHP Annual Meeting
The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares
Filip van Den Bosch¹, Siegfried Wassenberg², Boulos Haraoui³, Patrick Zueger⁴, Meijing Wu⁴, Ivan Lagunes Galindo⁴ and Andrew Ostor⁵, ¹Ghent University Hospital, Ghent, Belgium, ²Rheumazentrum Ratingen, Ratingen, Germany, ³Université de Montréal, Montreal, QC, Canada, ⁴AbbVie Inc., North Chicago, IL, ⁵Cabrini Medical Center, Melbourne, Australia
Background/Purpose: The AbbVie patient (pt) support program (PSP) is offered to pts prescribed adalimumab for RA and other indications. The purpose of this analysis was…
Abstract Number: 1610 • 2018 ACR/ARHP Annual Meeting
Incremental Benefits to Quality of Life Associated with Achieving Higher Levels of American College of Rheumatology Response and Skin Clearance in Patients with Psoriatic Arthritis
Josef S. Smolen¹, David Shrom², Chen-Yen Lin², Julie Birt², Georg Schett³ and Alice B Gottlieb⁴, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Eli Lilly and Company, Indianapolis, IN, ³Medical Clinic 3, Friedrich-Alexander University, Erlangen-Nuremberg, Germany, ⁴Department of Dermatology, New York Medical College, New York, NY
Background/Purpose: PsA is a chronic inflammatory disease associated with psoriasis. For optimal quality of life (QoL) improvements, all PsA symptoms should be managed. We examine…
Abstract Number: 1840 • 2018 ACR/ARHP Annual Meeting
Disease Activity in Rheumatoid Arthritis Patients Is Influenced By Countries’ Socioeconomics: Results from the Meteor Registry
Sytske Anne Bergstra¹, José Tavares Costa², David Vega-Morales³, Karen Salomon-Escoto⁴, Nimmisha Govind⁵, Cornelia F. Allaart¹ and Robert B.M. Landewé⁶, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ³Rheumatology, University Hospital “Dr. José Eleuterio González”, UANL, Monterrey, Mexico, ⁴University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, ⁵University of the Witwatersrand, Johannesburg, South Africa, ⁶Amsterdam Rheumatology & Immunology Center | Zuyderland Medical Center, Heerlen, Netherlands
Background/Purpose: The treatment and prognosis of rheumatoid arthritis (RA) patients have improved tremendously, but patients across the world may not benefit similarly. One of the…
Abstract Number: 2457 • 2018 ACR/ARHP Annual Meeting
Association between Biologic Dmards and Weight Change in Patients with Inflammatory Arthritis
Britney Jones¹, Imran Hassan², Walter P. Maksymowych³ and Elaine Yacyshyn⁴, ¹University of Alberta, Edmonton, AB, Canada, ²EPICORE Centre, University of Alberta, Edmonton, AB, Canada, ³CaRE Arthritis, Edmonton, AB, Canada, ⁴Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Inflammatory arthritis (IA) is a chronic disorder that encompasses rheumatoid and psoriatic arthritis. Rheumatoid cachexia is defined as elevated HDL, increased adiposity, and loss…
Abstract Number: 2643 • 2018 ACR/ARHP Annual Meeting
Sledai-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus
Zahi Touma¹, Murray Urowitz², Dafna D Gladman², Carrie Wagner³, Bei Zhou³, Robert Gordon³, Benjamin Hsu³, Marc Chevrier³ and Shawn Rose³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Krembil Research Institute, U of Toronto, Toronto, ON, Canada, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Ustekinumab (UST), a monoclonal antibody that targets the shared p40 subunit of the cytokines IL-12 & IL-23, is being investigated in patients (pts) w/…
Abstract Number: 2951 • 2018 ACR/ARHP Annual Meeting
Ustekinumab Treatment Response in SLE Is Associated with Changes in Type II but Not Type I Interferons
Jarrat Jordan¹, Kristen Sweet², Matteo Cesaroni¹, Keying Ma², Carol Franks², Loqmane Seridi², Jessica Schreiter³, Robert Gordon², Peter E. Lipsky⁴, Shawn Rose², Frédéric Baribaud², Matthew Loza² and Kim Campbell², ¹Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: We previously reported that treatment with ustekinumab (UST), an anti-IL-12/23 p40 neutralizing monoclonal antibody, improved global and organ-specific measures of disease activity in a…
Abstract Number: 322 • 2018 ACR/ARHP Annual Meeting
Swollen Joint Count Vs. RAPID3: Why a Discrepancy in Remission State?
Gary Craig¹ and Keith Knapp², ¹Discus Analytics LLC., Spokane, WA, ²Discus Analytics LLC, Spokane, WA
Background/Purpose: RA patients (pts) often have multiple comorbidities, and with multiple disease activity (DA) metrics available selecting an appropriate metric is vital. It remains an…
Abstract Number: 592 • 2018 ACR/ARHP Annual Meeting
Improved Response to Etanercept Is Associated with Serum Vitamin D Levels in Rheumatoid Arthritis
W Dankers¹, Pascal HP de Jong², S Heil³, S van den Berg³, A Weel⁴, JMW Hazes⁵, E Colin⁶ and Erik Lubberts⁷, ¹Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Clinincal Chemistry, Erasmus MC, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁵Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁶ZGT Almelo, Deventer, Netherlands, ⁷Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands
Background/Purpose: Although treatment of rheumatoid arthritis (RA) has significantly improved during the past decades, many patients do not adequately respond or become resistant to current…
Abstract Number: 1385 • 2018 ACR/ARHP Annual Meeting
Subjective Well-Being Among Rheumatoid Arthritis Patients
Goichi Kageyama^1,2, Akira Onishi³, Yo Ueda³, Kengo Akashi³, Sho Sendo³, Jun Saegusa³ and Akio Morinobu², ¹Department of Rheumatology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan, ²Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Subjective well-being (SWB) is a psychological construct that is synonymous with happiness. Many variables including age, sex, income, employment, and marital status are related…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].